KOSDAQElectrical Equipment460470

IVIM Technology

₩1,869▼ 14.66%2026-11-18 close
Market Cap
₩28.3B
Turnover
₩300M
Volume
160K
Shares out.
15.1M
PER
—
PBR
1.5×
EPS
-₩223
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Lumpy overseas orders keep IVIM in the red

Revenue jumped to KRW 2.98 billion in the second quarter of 2026 before falling to KRW 1.35 billion in the third quarter, while the operating loss widened to KRW 1.16 billion. Whether overseas equipment orders can steady quarterly results is the central issue.

  1. 1

    On disclosed figures, 2025 revenue rose 22.8% year on year to KRW 4.38 billion, yet the company still posted an operating loss of KRW 4.15 billion.

  2. 2

    The operating loss in the third quarter of 2026 was KRW 1.16 billion, a wider loss than both the prior quarter and the same quarter a year earlier.

  3. 3

    Based on press reports, first-half 2026 revenue reached KRW 3.05 billion, about 3.5 times the prior-year level.

  4. 4

    The share of microscope equipment sales fell from 83.3% in 2023 to 68.5% on a cumulative basis through the third quarter of 2025, while CRO services accounted for 9.5%.

  5. 5

    The debt ratio at the end of 2025 was 9.4% with total equity of KRW 27.6 billion, but operating cash flow was negative in each year from 2023 to 2025.

02

Business structure

IVIM Technology is a bioimaging equipment maker founded in 2017 as a KAIST faculty-founded venture, and it listed on KOSDAQ in 2024. Its core product, the intravital microscope (IVM), is used for in vivo cell imaging, drug efficacy testing and drug delivery imaging in living animals.

The business is organized into equipment sales, contract research (CRO) services and the development of AI-based medical devices. Equipment sales accounted for the largest share of revenue on a cumulative basis through the third quarter of 2025, with CRO services and imaging accessories making up much less.

The microscope share was higher in 2023, so the mix has shifted toward CRO and other revenue. The customer base has widened from universities and research institutes to global pharmaceutical companies, including Sanofi.

Exports are spread across the United States, China and Europe, with Revvity handling local sales in China. Overseas list prices are typically around USD 500,000, and maintenance contracts and consumables follow after installation.

In competition, the company's CEO has argued that overseas peers can image only one or two tissues at a time, while IVIM's technology handles about thirty. An AI medical device for detecting residual cancer cells during surgery is in development.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.7B-₩700M−42.5%
2025Q4₩1.8B-₩700M−40.3%
2026Q1₩76,802,009-₩1.5B−1896.8%
2026Q2₩3B-₩200M−6.6%
2026Q3₩1.4B-₩1.2B−85.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2023₩4.5B-₩2.9B-₩5B−64.6%−39.3%29.0%
2024₩3.6B-₩4.3B-₩4B−120.9%−12.8%11.6%
2025₩4.4B-₩4.2B-₩3.8B−94.9%−13.8%9.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-12

04

Earnings analysis

On disclosed annual figures, revenue fell from KRW 4.5 billion in 2023 to KRW 3.56 billion in 2024, a 20.7% decline, before recovering to KRW 4.38 billion in 2025, a 22.8% increase. Among 2023 to 2025, 2023 was the largest revenue year and 2024 the smallest.

Operating losses were KRW 2.91 billion in 2023, KRW 4.31 billion in 2024 and KRW 4.15 billion in 2025, with operating margins of -64.6%, -120.9% and -94.9%. In 2024 the operating loss widened as revenue declined, while in 2025 the loss narrowed as revenue recovered.

The loss attributable to controlling shareholders was KRW 5.04 billion in 2023, KRW 4 billion in 2024 and KRW 3.8 billion in 2025, and the net loss including non-controlling interests was the same in each year.

At the end of 2025, total equity was KRW 27.6 billion, total liabilities were KRW 2.59 billion and the debt ratio was 9.4%. Operating cash flow was KRW -3.45 billion in 2023, KRW -6.93 billion in 2024 and KRW -4.25 billion in 2025.

On a quarterly basis, revenue was KRW 1.65 billion in the third quarter of 2025 and KRW 1.85 billion in the fourth quarter, an 11.8% quarter-on-quarter increase, before falling to KRW 76.8 million in the first quarter of 2026, a 95.8% decline.

Revenue rose to KRW 2.98 billion in the second quarter of 2026, up 3,776.8% from the prior quarter, and then fell to KRW 1.35 billion in the third quarter, down 54.6% quarter on quarter and 18.2% year on year.

Operating losses ran at KRW 704 million, KRW 745 million, KRW 1.46 billion, KRW 195 million and KRW 1.16 billion over the five quarters from the third quarter of 2025 to the third quarter of 2026, so the company has recorded losses for five consecutive quarters.

The loss attributable to controlling shareholders was KRW 588 million, KRW 619 million, KRW 1.36 billion, KRW 114 million and KRW 1.27 billion over the same quarters, and the four-quarter total from the fourth quarter of 2025 through the third quarter of 2026 was KRW 3.37 billion.

Equipment sales depend on long purchase decisions, as the company's half-year report indicates a typical lead of about two years, which helps explain the sharp quarter-to-quarter swings.

05

Industry analysis

Demand for intravital microscopy comes from pharmaceutical and biotech research that tests how drug candidates move and reach target cells inside living bodies. A 2024 securities report projected the global two-photon microscopy market to grow at an average annual rate of 6.9% from 2022 to 2031.

The global move to reduce animal testing could expand demand for alternative technologies over time. Analysts also note that protocol standardization and equipment costs limit the near-term shift to organoid-based microscopes.

A 2026 securities report viewed this gap as transitional demand that the company's equipment can serve. The company's two-photon design is described as faster in scanning than confocal systems, with heating plates for keeping animals alive and AI image correction.

In competition, the company is presented as a leader in laser-based intravital microscopy, with about twenty institutions reported to have adopted its IVM products. No direct quantitative comparison with domestic peers was confirmed, so market share cannot be stated.

Research IVM systems have been reported at roughly KRW 300 million to KRW 600 million per unit. The sector classification is electrical equipment, while the business is classified as other optical instrument manufacturing.

06

Outlook

The company said it began scaling its CRO business using its microscopy solutions in the second half of 2026. The CRO service covers validation of drug candidates and basic medical research for biotech firms and university labs that cannot easily buy equipment themselves.

According to a September 2026 press report, the company supplied microscopes to the National Institute of Environmental Health Sciences (NIEHS) and Yale University in succession, and secured orders of about KRW 1.07 billion over two consecutive days.

It also signed new distributor agreements in Vietnam and Indonesia, and the CEO said the company is preparing bulk supply contracts beyond individual equipment sales.

A 2026 securities report projected that four to five of five to six Revvity-linked projects would be recognized as revenue within 2026, alongside roughly ten demonstrations ongoing across Korea, China, the United States and Europe.

The medical device is being developed to detect residual cancer cells during surgery, but the timing of regulatory approval for clinical trials has not been confirmed in the available material. A 2024 report said the company was preparing an IND application.

Management has stated a goal of reaching breakeven in fiscal 2027. Given the wide swings in quarterly revenue, whether large overseas orders recur will determine progress toward that target.

07

Valuation

PER
—
PBR
1.5×
ROE
-12.7%
EPS
-₩223
BPS
₩1,650
Dividend per share
₩0

Because the company has posted losses for the last four quarters, the price-to-earnings ratio cannot be calculated. The price-to-book ratio, which compares the share price with book equity, therefore serves as the main reference point.

The price-to-book ratio is above 1 times, which means the share price sits above book value. This structure implies that growth from overseas orders and CRO services is reflected in the price beyond the balance sheet assets. The company pays no dividend, so yield-based comparisons do not apply.

Earnings-based multiples will become meaningful once operating losses narrow and the company turns profitable, and management's breakeven target for fiscal 2027 is the starting point for that comparison. A debt ratio of 9.4% and total equity of KRW 27.6 billion indicate a relatively light debt burden.

Operating cash flow was negative in each year from 2023 to 2025, which is also a fact to weigh in any asset-based assessment.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-12

08

Bull factors

Overseas orders and wider distribution

According to a September 2026 press report, the company supplied NIEHS and Yale University in succession, and first-half revenue reached about 3.5 times the prior-year level. The CEO said results across all business segments roughly doubled from the prior year. New distributor agreements in Southeast Asia also support the expansion of sales channels.

Shift of CRO customers toward biotech

A March 2026 securities report noted that the CRO business is shifting its main customers from research institutes toward biotech firms. The company also has a path in which customers first use CRO services and then buy equipment.

Balance sheet capacity and breakeven target

Total equity at the end of 2025 was KRW 27.6 billion with a debt ratio of 9.4%, a relatively light debt burden. Management said it aims to reach breakeven next year. If profitability improves, the current capital base could cushion business expansion.

09

Bear factors

Persistent losses and a wider loss in Q3 2026

The third-quarter 2026 operating loss was KRW 1.16 billion, wider than both the prior quarter and the same quarter a year earlier. The company has recorded losses for five consecutive quarters through the third quarter of 2026.

The loss attributable to controlling shareholders over the last four quarters totaled KRW 3.37 billion. No clear timeline for returning to profit has been presented.

Large swings in quarterly revenue

First-quarter 2026 revenue fell to KRW 76.8 million, a 95.8% quarter-on-quarter decline, and third-quarter revenue fell 54.6% to KRW 1.35 billion. Purchase decisions for these instruments typically take about two years, so a few large orders drive quarterly results. Revenue tends to cluster or disappear depending on when orders close.

Weak cash generation

Operating cash flow was KRW -3.45 billion in 2023, KRW -6.93 billion in 2024 and KRW -4.25 billion in 2025, negative in all three years. Even when equipment revenue is recognized, cash generation depends on collecting payments and building recurring maintenance revenue. If cash flow does not improve, the company may rely on its capital base for longer.

10

Risk factors

Research policy and demand shifts

The shift away from animal testing is seen as fitting the transitional phase of demand for the company's equipment. Over the long term, organoid-based alternatives could reduce demand for animal-based microscopes. Whether the company grows alongside such alternatives remains unconfirmed. Changes in research budgets could also affect the pace of orders.

Timing of medical device commercialization

The AI medical device aims to identify cancer cells during surgery, but a 2024 report described the company as preparing an IND application. Approval and clinical timing are uncertain, making the commercialization date difficult to pin down. Until device revenue begins, results will depend on equipment sales and CRO services.

Lock-up shares and supply

A lock-up table in a 2026 securities report lists a return date of August 5, 2027. If shares are released around that time, they could affect supply and demand. Given volatile earnings, supply factors overlapping with earnings swings could make the share price respond more strongly to non-earnings factors.

11

What to watch next

  1. End of December 2026

    Whether the targeted recognition of four to five Revvity-linked projects as 2026 revenue is achieved by year-end. The result will show how concentrated overseas equipment revenue is at year-end.

  2. By March 31, 2027

    The deadline for submitting the 2026 annual report. Annual revenue, operating results and operating cash flow for 2026 will be disclosed, and fourth-quarter 2026 results will enter the official record.

  3. By May 15, 2027

    The deadline for the first-quarter 2027 quarterly report. It will show whether operating losses have narrowed since the third quarter of 2026 and whether quarterly revenue swings have moderated.

  4. August 5, 2027

    The lock-up return date listed in the securities report table. Whether these shares enter circulation can affect supply and demand.

  5. During fiscal 2027

    Whether management's breakeven target for next year shows up in actual operating profit. The 2027 annual report will confirm this on a full-year basis.

12

Overall view

IVIM Technology runs equipment sales and CRO services in parallel. Revenue rose 22.8% in 2025, but the operating loss of KRW 4.15 billion kept the company in the red.

Quarterly revenue swung sharply through 2026, from KRW 76.8 million in the first quarter to KRW 2.98 billion in the second and KRW 1.35 billion in the third, while the third-quarter operating loss widened to KRW 1.16 billion.

Overseas orders from NIEHS and Yale continued, and distribution is expanding in Southeast Asia. Equipment purchase decisions take a long time, so quarterly volatility is likely to remain high.

On the balance sheet, a debt ratio of 9.4% and total equity of KRW 27.6 billion indicate a light debt burden, but operating cash flow was negative in each year from 2023 to 2025. Management's breakeven target for fiscal 2027 will be confirmed in future annual reports.

Bullish factors such as overseas order growth and bearish factors such as continued losses coexist, and this report does not assume a direction for the share price. It contains no investment opinion or target price.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. jobkorea.co.kr
  2. thevc.kr
  3. saramin.co.kr
  4. ibric.org
  5. incruit.com
  6. pharm.edaily.co.kr
  7. m.jobkorea.co.kr
  8. hitnews.co.kr
  9. thebionews.net
  10. eugenefn.com
  11. samsungpop.com
  12. pharm.edaily.co.kr
  13. thebionews.net
  14. fnnews.com
  15. supple.kr
  16. news.bizwatch.co.kr

Report written 2026-11-13 · Data as of 2026-11-12

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis